ArticleClinical infectious diseases : an official publication of the Infectious Diseases Society of America2025
Real-world Evaluation of the Effectiveness of Sinopharm COVID-19 Vaccine Against Symptomatic COVID-19 in an Omicron-Dominant Setting in Mozambique: A Test-Negative, Case-Control Study.
Article in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Artificial Intelligence Integrated Smart Medical Imaging Lab Framework for Enhanced Diagnosis and Treatment of Pandemic-Prone Diseases.Health science reports · 2026Article
- Overcoming Vaccine Inequities and Research Gaps in Africa: Challenges and Opportunities Identified During the COVID-19 Pandemic.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
29 authors.
Funding
Abstract
backgroundWe evaluated the effectiveness of the Sinopharm coronavirus disease 2019 (COVID-19) vaccine, introduced in Mozambique, against the Omicron variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), prevalent from March 2022 to December 2023.
methodsA test-negative case-control study was nested in a community-based enhanced COVID-19 surveillance in seven healthcare facilities including mobile testing stations in the Dondo District, Mozambique, between March 2022 and December 2023. Participants were individuals aged ≥2 years with COVID-19-like symptoms for <10 days. Cases were those with polymerase chain reaction (PCR)-confirmed COVID-19. For each case, three PCR test-negative controls were matched, according to age (±5 years), sex, and date of PCR test (±7 days). Follow-up for all cases was conducted until disease resolution. Vaccine protection was assessed according to the association between complete vaccination and SARS-CoV-2 disease onset ≥14 days after vaccination.
resultsThe study did not reach the targeted sample size, and only a third were analyzed. A total of 253 cases were matched to 759 test-negative controls by age, sex, and testing date, a process known as matching. Among cases, 41% had one dose of Sinopharm, 53% had two doses, and 6% were unvaccinated. Among the test-negative controls, 37% had 1 dose, 57% had two doses, and 7% were unvaccinated. The adjusted vaccine effectiveness, calculated using matching and adjusted for age and PCR test date, was 18.0% (95% confidence interval, -85.3 to 63.7; P = .63). No COVID-19-positive participants required hospitalization.
conclusionsIn an Omicron-dominant setting, two doses of the Sinopharm vaccine did not show significant protection against symptomatic COVID-19. However, as our analysis was based on data from only a third of enrolled individuals with confirmed vaccination status, these findings should be interpreted with caution. Our results underscore the importance of real-time vaccine effectiveness evaluations to inform optimal rollout strategies in low- and middle-income countries.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.